What Is Cancer?
nasopharyngeal carcinoma treatment :: Article Creator Penpulimab Approved For Nonkeratinizing Nasopharyngeal Carcinoma The Food and Drug Administration (FDA) has approved penpulimab-kcqx, a programmed death receptor-1 (PD-1)-blocking antibody, in combination with either cisplatin or carboplatin and gemcitabine, for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC); or as a single agent, for the treatment of adults with metastatic nonkeratinizing NPC with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. The approval of penpulimab-kcqx as first-line treatment was based on the randomized, double-blind AK105-304 trial (ClinicalTrials.Gov Identifier: NCT04974398), which included 291 participants with recurrent NPC with local-regional recurrence and/or distant metastasis occurring at least 6 months after curative intent treatment completi...